Pharmaceutical Drugs Is Fastest Growing Segment Fueling The Growth Of Controlled Substance Market
Controlled Substance Market |
The
global Controlled Substance Market is estimated to be valued at US$ 41.8 Bn in 2023 and is expected to
exhibit a CAGR of 4.9% over the
forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights.
Market Overview:
Controlled substances are pharmaceutical drugs that are regulated by
governments and placed under special rules due to potential for abuse or
addiction. They are used to treat various conditions like pain, anxiety,
depression and insomnia. Controlled substances offer effective treatment
options but needs to be used carefully as prescribed to avoid abuse.
Market key trends:
Regulations around prescription and dispensing of controlled substances are
getting stricter globally in order to curb the ongoing opioid crisis.
Governments are implementing electronic tracking systems to monitor controlled
substances from manufacturers to end users. Strict enforcement on
overprescription by physicians is being done through prescription drug
monitoring programs. Newer controlled substances are being introduced as
alternatives to opioids for pain management which are less addictive and have
lower abuse potential. Research is also ongoing for developing abuse-deterrent
formulations for controlled drugs.
Segment Analysis
The global controlled substance market can be segmented into narcotic drugs,
stimulants, depressants, hallucinogens, and anabolic steroids. Among these,
narcotic drugs represent the largest and fastest-growing segment, accounting
for over 35% of the overall market share in 2023. This is because of their
widespread medical application in pain management, especially for opioids like
morphine and codeine. Their effectiveness and easy availability have further
boosted the sales of narcotic drugs globally.
Key Takeaways
The
Global Controlled Substance Market Demand
is expected to witness high growth, exhibiting CAGR of 4.9% over the forecast period, due to increasing prevalence
of chronic pain and rise in geriatric population suffering from arthritis,
cancer, and other diseases requiring pain management therapies. The market size
is projected to reach US$ 41.8 Bn in 2023.
North America accounted for the largest share of over 40% of the global
controlled substance market in 2023 due to growing consumption of prescription
opioids in pain management and easy availability of these drugs in the region.
Asia Pacific is expected to witness the highest CAGR during the forecast period
owing to the increasing uptake of medical marijuana and rapid establishment of
cannabis dispensaries in emerging countries like China, India, Australia, and
South Korea.
Key
players operating in the controlled substance market include Johnson &
Johnson, Pfizer, Sanofi, Merck & Co., Gilead Sciences, Amgen, Novartis,
AbbVie, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Teva
Pharmaceutical, Bayer, Novo Nordisk, Allergan, Takeda Pharmaceutical,
Boehringer Ingelheim, Aspen Pharmacare, and Astellas Pharma.
Read
More:
Comments
Post a Comment